Chemours (NYSE:CC) PT Raised to $37.00 at UBS Group

Chemours (NYSE:CCGet Rating) had its price target boosted by UBS Group from $35.00 to $37.00 in a research report report published on Friday, Marketbeat.com reports. They currently have a neutral rating on the specialty chemicals company’s stock.

A number of other research analysts have also recently weighed in on the stock. Barclays lifted their price objective on shares of Chemours from $37.00 to $46.00 in a report on Monday, May 9th. Bank of America cut shares of Chemours from a buy rating to a neutral rating and cut their target price for the stock from $48.00 to $44.00 in a research note on Tuesday, June 14th. Finally, StockNews.com cut shares of Chemours from a strong-buy rating to a buy rating in a research note on Tuesday, June 21st. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $39.60.

Chemours Stock Down 1.3 %

CC opened at $35.12 on Friday. Chemours has a fifty-two week low of $22.56 and a fifty-two week high of $44.95. The company has a debt-to-equity ratio of 3.01, a quick ratio of 1.27 and a current ratio of 1.91. The company has a fifty day moving average of $35.54 and a two-hundred day moving average of $33.71. The stock has a market capitalization of $5.46 billion, a price-to-earnings ratio of 6.55, a PEG ratio of 0.50 and a beta of 1.82.

Chemours (NYSE:CCGet Rating) last released its quarterly earnings data on Thursday, July 28th. The specialty chemicals company reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.47. Chemours had a net margin of 12.72% and a return on equity of 79.77%. The company had revenue of $1.92 billion during the quarter, compared to analysts’ expectations of $1.84 billion. During the same quarter in the previous year, the company earned $1.20 earnings per share. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. On average, research analysts expect that Chemours will post 5.24 earnings per share for the current year.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 15th. Stockholders of record on Monday, August 15th will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Friday, August 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.85%. Chemours’s dividend payout ratio is currently 18.66%.

Insider Activity at Chemours

In related news, SVP Alvenia Scarborough sold 7,249 shares of the company’s stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $40.42, for a total transaction of $293,004.58. Following the completion of the sale, the senior vice president now owns 12,322 shares of the company’s stock, valued at approximately $498,055.24. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Alisha Bellezza sold 14,365 shares of the company’s stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $40.48, for a total transaction of $581,495.20. Following the completion of the sale, the insider now owns 38,797 shares of the company’s stock, valued at approximately $1,570,502.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Alvenia Scarborough sold 7,249 shares of the business’s stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $40.42, for a total transaction of $293,004.58. Following the completion of the transaction, the senior vice president now owns 12,322 shares in the company, valued at $498,055.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 296,280 shares of company stock valued at $11,989,133. Corporate insiders own 3.04% of the company’s stock.

Hedge Funds Weigh In On Chemours

Institutional investors and hedge funds have recently bought and sold shares of the company. Sageworth Trust Co of South Dakota acquired a new position in Chemours in the 4th quarter valued at about $26,000. AdvisorNet Financial Inc lifted its holdings in shares of Chemours by 63.2% in the 1st quarter. AdvisorNet Financial Inc now owns 785 shares of the specialty chemicals company’s stock worth $25,000 after acquiring an additional 304 shares during the last quarter. Asset Management One Co. Ltd. acquired a new position in shares of Chemours in the 2nd quarter worth approximately $25,000. Prospera Financial Services Inc acquired a new position in shares of Chemours in the 1st quarter worth approximately $29,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Chemours by 274.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,014 shares of the specialty chemicals company’s stock worth $34,000 after acquiring an additional 743 shares during the last quarter. 76.38% of the stock is currently owned by institutional investors and hedge funds.

Chemours Company Profile

(Get Rating)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.